



Tomáš Zábranský, Viktor Mravčík
Editors:
Danica Thanki and Julian Vicente
March 2014
LITERATURE REVIEW
The levels of use of opioids, 
amphetamines and cocaine and 
associated levels of harm: 













page 2 of 53 
Summary 
This report presents the findings of a literature review to identify the most frequently occurring 
patterns of use and their relation to harm in users of opioids, powder and crack cocaine, and 
meth/amphetamine. The behavioural factors that were studied included: frequency of use, 
duration of use, routes of administration, drug type, dose, severity of dependence, and (the 
presence of) polydrug use. 
Research on stimulants covers a relatively broad spectrum of patterns and severity, and thus 
provides some indications of the levels of use that are more harmful than others. Similar 
evidence is relatively scarce for opioids, where the overwhelming majority of studies 
concentrate only on the most risky injecting and addictive use. 
For cocaine and amphetamines, it appears that weekly and higher frequency of use and 
patterns involving heavy periods of continuous use (bingeing) are related to increased 
prospective risk or actual existence of harms. Similar conclusion cannot be made for opioids, 
although research provides some indication of controlled use of heroin on a weekly and 
monthly (or less frequent) basis. Similarly, some evidence exists that crystal forms of 
stimulants — crystal methamphetamine and crack cocaine — are often positively associated 
with more harmful patterns of use and more severe consequences, whereas very little 
attention is paid in the literature to the different forms of heroin/opioids. Routes of 
administration range from injecting, through smoking and inhaling, to snorting and oral 
consumption when ranked from the riskiest to less risky routes, although the less risky routes 
of snorting and swallowing are not considered to be risk-free behaviours. Frequency and 
duration of use are likely moderators of harms associated with routes of administration. 
Injectors are at higher risk of transmission of drug-related infectious diseases and death, the 
former being a function of the frequency and patterns of injecting. 
Polydrug use, although not a primary concern of the present review, proved to be an 
extremely significant confounding factor of any harm associated with use of these 
substances. It indicates a particular level of compulsivity and is closely associated with higher 





This publication is based on the EMCDDA contract ‘CT.12.EPI.0.046.1.0’ – ‘Assistance to 
EMCDDA in some aspects of the process of problem drug use key indicator revision and re-
conceptualisation’, Part 1: Literature review aiming to support the development of theoretical 
definitions of subcategories of the revised problem drug use (PDU) EMCDDA indicator area. 
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1. Introduction: context and rationale 
The present report is the first output (of three) of the project assisting the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) during the process of revising the 
key indicator ‘problem drug use’ (PDU). PDU is one of the five harmonised key indicators of 
drug epidemiology (5 KIs) developed by the EMCDDA and the REITOX network to monitor 
various aspects of the drug phenomena in Europe. The indicator was introduced to estimate 
the prevalence of the most severe forms of drug use (e.g. injecting drug use, heroin and 
cocaine dependence, etc.), which cannot be assessed through general population surveys 
due to low social acceptance of such behaviours and their hidden nature. Drug users with the 
most risky patterns feed most of the demand for specialised treatment of drug-related 
disorders and bear and create the vast majority of the health and social consequences of 
drug use (Hartnoll, 1997). Until recently, PDU has been defined as injecting drug use and/or 
long-term and regular use of opioids, cocaine or amphetamines (EMCDDA, 2009). In 
practice, the indicator has focused mainly on opioid — or rather, heroin — use. While this was 
appropriate for the drug situation when the indicator was established, the PDU indicator is 
now in need of systematic revision due to changes in the drug field in recent years, the 
development of new tools for assessing problematic forms of other drugs (e.g. cannabis), and 
an improvement in the quality and availability of the necessary data. 
The process of revising the PDU indicator started in 2004 and peaked in 2012 when the final 
revision proposal was drafted and approved at the EMCDDA Heads of focal points meeting in 
Lisbon. The revised indicator focuses on high-risk drug use. The term high-risk drug use 
means ‘recurrent drug use that is causing actual harms (negative consequences) to the 
person (including dependence, but also other health, psychological or social problems) or is 
placing the person at a high probability/risk of suffering such harms’ (EMCDDA, 2012b). The 
conceptual framework has been translated into a definition, further operationalised by drug: 
‘High-risk drug use is measured as the use of psychoactive substances by high-risk pattern 
(e.g. intensively) and/or by high-risk routes of administration in the last 12 months’ (EMCDDA, 
2012b). 
There was a need for further operationalisation of this definition into case definitions at the 
level of the data source for individual substances, in an attempt to improve European-level 
comparability of the estimates that were obtained. The literature review conducted within this 
contract project and presented here aims to provide the scientific background for decisions 
about the suggested cut-off points between cases and non-cases included in the estimated 
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2. Methodology 
2.1. Aims and scope of the literature review 
This literature review has looked into the relationship between levels of use (i.e., frequency, 
quantity) and harms. This was in order to explore the thin borderline on a continuum between 
(i) experimental/occasional or low-level users, who typically experience low harm and (ii) 
users with heavier, more severe forms of drug use, associated with more severe harm. In this 
context the review also explored the cut-off points of this distinction that were used in the 
existing scientific literature, including the (methodological) instruments that are routinely used. 
The review aims to provide some guidance on these thresholds for opioids, cocaine/crack 
cocaine and amphetamines, and for different routes of administration. 
Substances considered in the first stage were those included in the current PDU definition. 
Namely, case definitions were created for:  
 intensive opioids use; 
 intensive crack cocaine smoking; 
 intensive powder cocaine use — snorting; 
 intensive amphetamine use (amphetamine and methamphetamine) — smoking, 
snorting, and swallowing; and 
 injecting of any of the above substances, and of any other (illicit) psychotropic 
substance. 
Cannabis and some other substances, including mephedrone and other (injectable) new 
psychotropic substances, were not included in the review. Polydrug use was not considered 
as an independent category, but, if available, information on the possible association of not-
included substance use with increased risk and/or harm was considered.  
Harms associated with routes of administration were assessed by substance where studies 
were available. 
2.2. Methods 
A systematic literature review was employed as follows: (i) Various combinations of search 
strings (see Table 2.1 for the list of key words used) were applied on selected scientific 
databases and search engines. The search string matrix was updated several times during 
the review process. (ii) Papers that were pre-selected on the basis of their title and abstract 
were downloaded to the citation manager together with their full text. (iii) All duplicates, 
multiple entries and irrelevant papers were removed and the remaining papers were scanned 
to identify the information that was of interest. (iv) When a relevant study was cited that had 
not already been identified by database queries, it was added to the working database. 
A total of 408 entries were collected for initial analysis, of which 20 studies on opioids, 25 on 
cocaine and 17 on amphetamines were included in the final review. No formal criteria were 
applied to assess the quality of the studies that were included.  
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Table 2.1: Search string matrix 
Substance  Concept/severity  Indicator 
drug% OR 
substance% 
 risk OR harm OR complication% 
OR consequence% 
 frequency of use 
heroin OR opiate% 
OR opioid% 
 (problem OR problematic OR 
harmful OR hazardous OR 
intensive OR severe OR dangerous 
OR heavy OR high risk) AND use 
 dose OR amount OR daily 
dose OR intensity of use 
cocaine*  need for treatment OR need for 
intervention  










 individual OR population  route OR smok% OR inject% 
OR sniff% OR chasing OR 
nasal OR oral OR snort% OR 
swallow%** 
  addiction OR dependence   
Notes: 
* ‘Crack’ has been dropped due to its wide range of meanings. It was assumed that any paper on ‘crack 
cocaine’ would also contain the word ‘cocaine’. 
** No specific search by route of administration was performed. Routes were assessed in a substance-
specific manner.  
2.2.1. Databases and other sources 
A first round of searching was performed on scientific databases: PubMed, EBSCO Host 
(Academic Search Complete, PsycARTICLES, PsycINFO, SocINDEX with Full Text), and 
ScienceDirect. Subsequently, Google Scholar search engine was used to identify possible 
omissions and to reduce search errors. Also, any relevant papers previously available to the 
research team were included into the analysis.  
2.2.2. Inclusion and exclusion criteria 
In order for a paper to be included in the analysis, it had to describe the association of 
patterns of use of a specific drug/s (or involve a comparison of patterns of use) with adverse 
effects at the individual level. Studies that did not consider a specific substance in the 
analysis (i.e. those that focused only on polydrug use or on any drug use — the latter typically 
based on general population and youth surveys) were not included. Similarly, studies 
comparing users versus non-users that disregarded patterns of use were not considered.  
Other inclusion criteria were as follows:  
 full text written in English; 
 published in 2000 or later; 
 peer-reviewed; 
 performed on human subjects without a medical condition (excluding drug-related 
disorders); 
 using predominantly quantitative methodology. 
The condition of peer review was dropped when a document had been cited by a peer-
reviewed paper (it was assumed that the quality of such research had been evaluated by the 
referring author and within the revision process). The reference time frame of the search 
(studies published from 2000 onwards) was chosen in order to capture the current situation in 
the literature and recent developments, occurring at the same time as the recent changes in 
the European drug situation and the resulting revision of PDU indicator. Nevertheless, older 
research was also occasionally included in the sample of studies when the authors 
considered it to be important to this analysis.  
page 7 of 53 
Studies estimating the prevalence of problem drug use were excluded, as they are not 
examining the association between level of use and level of harm and they generally use the 
EMCCDA definition of problem drug use (or a similar definition). On the other hand, papers 
that either contained theoretical (conceptual) examination of non-experimental drug use or 
reviewed the consequences of such use were included. 
3. Theoretical framework 
Since harmful use, abuse and dependence on illicit drugs and risky patterns of drug 
administration carry a considerable burden for individuals and societies, there have always 
been attempts to organise and classify drugs according to their harmfulness. Recently, 
several attempts have been made to rank psychoactive substances according to the harms 
they are causing to individuals and communities. To provide a theoretical framework for the 
present literature review, this section presents an overview of types of harms as they were 
employed in the context of such research. Some theoretical limitations and considerations will 
also be discussed. 
3.1. Typology of harms 
Research on the adverse consequences of drug use is extremely diverse in terms of 
disciplines, methods, sampling strategies and sample sizes, as well as the substances 
considered and the effects, risks and consequences associated with varying patterns of their 
use. In particular, the outcomes range from a single minor health consequence (e.g. 
reversible hearing loss) to relatively complex conditions (e.g. social functioning impairment 
measured by specific instruments). Thus, for the purpose of the review, a systematic 
approach had to be employed. Two different approaches found in the literature are presented 
below in order to contextualise or, to a certain extent, classify the approach taken. 
Approach I 
Best et al. (2003) distinguish between acute adverse effects that are not associated with 
frequency of use, and chronic adverse effects that consist of dangers that are cumulative with 
increased use. Both categories are further divided into physical, psychological/psychiatric, 
and social adverse effects. Authors also acknowledge a set of factors mediating or 
moderating harms associated with drugs. Among these factors are: aspects of ingestion 
(route of administration, dose and purity), use in combination (use with other drugs either 
concurrently or consecutively), availability (how easily accessible is the substance and how 
this impacts upon use), legal situation (both the law and its implementation around the use of 
the substance), social context (consequences of set, setting and social milieu on 
dangerousness), age and developmental issues (the likely impact of age of onset and use on 
harm), individual vulnerability (particular individuals or groups susceptible to specific harms), 
and incapacitation (the effect of imprisonment or treatment on patterns of use — including 
substitution with other drugs).  
In line with this typology, the focus of the present review has been on chronic effects of drug 
use. Only selected characteristics of patterns of use and routes of administration could be 
included in the summary text of all the above listed moderating factors (due to scarce data on 
most domains); however, some others were also taken into the inclusion criteria (e.g., 
polydrug use, characteristics of the study population) and all the relevant information from the 
studies used is summarised in the respective tables.  
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Approach II 
In their recently published work, Nutt et al. (2010) (1) developed a model of 16 evaluation 
criteria organised by harms to users (nine criteria) and harms to others (seven criteria), as 
shown in Figure 3.1. Harms to users are generally associated with the characteristics of drugs 
(e.g. toxicity of a substance) and patterns of use (e.g. frequency of use, route of 
administration), while community/society harms are connected to prevalence. Following this 
logic, even a deadly poisonous substance ranks low on societal harms if nobody uses it. 
Figure 3.1: Harms organised by harms to users and harms to others, and clustered 
under physical, psychological, and social effects (source: Nutt el al., 2010) 
 
Within this review, only the ‘harms to users’ listed by this model were relevant. Only patterns 
of use (in terms of frequency, route, etc.) were considered; the characteristics of the drug 
itself (e.g., intrinsic lethality) were not considered, since focus of the review in terms of the 
(types of) drugs that were included was predefined. Therefore, with regard to mortality and 
dependence, for example, we were not looking for the propensity of the drug to create 
dependence or to identify a lethal dose (these were satisfactorily assessed elsewhere — see 
Gable, 2004), but instead for the patterns of use that put users at risk of harmful 
consequences such as overdose or developing dependence.  
                                                     
(1) For the sake of completeness, it should be noted that the nine criteria describing harms to users were previously 
evaluated and ranked by Nutt et al. (2007) for the UK situation, and subsequently by van Amsterdam et al. (2010) for 
the Netherlands context. Later, Morgan et al. (2010) repeated the same approach on the drug using population in the 
UK and received comparable results.  
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3.2. Theoretical and methodological considerations 
Any assessment of harms related to drug use has to take into account some terminological 
and methodological considerations. First, as pointed out by Best et al. (2003), one has to 
make a clear distinction between ‘harms caused by’ and ‘harms associated with’ drug use: ‘A 
person who dies from heart disease may well have had their heart weakened by prolonged 
excessive drinking, but may also have had a poor diet, little exercise and a stressful lifestyle. 
In this way, alcohol may well be an enabling condition rather than the single causal 
determinant, complicating the question of “cause”’ (Best et al., 2003, p. 6). Hence, it should 
be noted that any conclusions made either within or on the basis of this review concern 
merely an association. This point will become even more apparent when one realises that 
only a few studies included in this review were designed as longitudinal cohort studies, while 
the majority refer to findings of simple comparative methods within cross-sectional surveys. 
The heterogeneity of the research on drug-related harms is enormous and comparability of 
findings is very limited. Room (2006) suggests studying harm among heavy users in order to 
achieve comparable results on severity of health effects of a substance. The present review 
set out to target studies conducted among heavy or chronic users. However, although many 
studies claimed to include data on such users, the actual recruitment criteria used were 
relatively soft and inclusive, often simply requiring any use of the substance within the 
specified period of time. The cut-off points related to drug use intensity, chosen by 
researchers to distinguish ‘lighter’ from ‘heavier’ users are reported, where available. If no 
such cut-off points were applied or a certain characteristic was used in the analysis as a 
continuous variable, we report sample average (together with standard deviation if available) 
of the populations studied, in order to roughly describe the distribution of the particular 
characteristic in the studied sample.  
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4. Results of the literature review 
This section summarises the findings of literature review by substance. The sections by 
substance are further sub-divided into two sections: qualitative information, mainly based on 
published literature reviews and their results, generally reported in a qualitative manner; and 
behavioural factors, based on quantitative studies testing the associations between certain 
patterns of use and negative outcomes. 
4.1. Opioids 
Heroin and other opioids are the most prevalent drugs among problem drug users in the 
European Union (EU). Heroin used to account for the majority of people entering drug 
treatment in the EU and it still constitutes the highest proportion of drug-related treatment 
admissions. Injecting, as the most dangerous route of drug administration, is typically closely 
linked to the use of heroin. Opioids also account for the vast majority of drug-related deaths in 
Europe (EMCDDA, 2012a). These associations between heroin and problematic patterns of 
use have had a substantial impact on the direction of the related research, which focuses 
mainly on overdose and dependence with very little attention paid to controlled use of opioids 
(Zinberg, 1984).  
Among populations of opioid users there seems to be a clear dichotomy between small and 
sporadically studied groups of users controlling their opioid use, and populations of heavy 
and, as a rule, dependent and daily users, which form the majority of studied and known 
opioid users. Most studies only research the latter group of heavy, dependent users, and 
presume that drug-related harm will affect all members of the group; therefore they only study 
the extent of such harm.  
4.1.1. Harms associated with opioids — qualitative information 
Heroin exists in a variety of different forms — in salt or base forms — that make a substantial 
difference to its suitability for use by different routes of administration. Injecting and smoking 
are the most prevalent across Europe; however, intranasal consumption is also highly 
prevalent in some countries (Strang et al., 2005, EMCDDA, 2012a). The overall transition to 
smoking and snorting witnessed in the last two decades may be related to increased purity of 
heroin in some countries (De La Fuente et al., 1996; Epstein and Gfroerer, 1998; Gruber et 
al., 2007). 
The major harms associated with the use of opioids are addiction and overdose. The 
propensity of heroin users to develop a serious addiction accompanied by painful, although 
not life-threatening, withdrawal symptoms puts the drug among the most addictive 
substances. The length of time between onset of abuse and dependence has been studied to 
provide a bridge between research on the addictive liability of drugs and on individuals’ 
liability to addiction, with opioids (together with cocaine) being the most addictive drugs 
(Ridenour et al., 2005). 
Opioids are present in the vast majority of drug-related deaths in Europe. Depression of 
breathing rate and blood pressure resulting in respiratory arrest is the primary cause of death 
by heroin overdose. Common correlates of overdose fatality are a long history of opiate 
dependence, a high level of opiate dependence, recent abstinence (due to imprisonment or 
detoxification) and concurrent use of other drugs (particularly alcohol and benzodiazepines) 
(Best et al., 2003; Sporer, 1999; Sanchez-Carbonell et al., 1988). Opioid overdose is 
traditionally associated with injecting as it delivers large amount of the drug and the user has 
less control over the intake (Degenhardt et al., 2011a; Darke and Hall, 2003; Warner-Smith et 
al., 2001; Darke and Zador, 1996; Hickman et al., 2003). 
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Association with other health consequences and impairments in psychosocial functioning are 
also described for opioids. These include suppression of the immune system, social 
deprivation and malnutrition, chronic constipation, respiratory complaints, menstrual 
irregularity, tooth decay, poor living conditions, neuropsychological complications, poor 
overall health, crime involvement and disrupted relationships (Best et al., 2003; Rosen et al., 
2011; Gruber et al., 2007). 
Injecting associated mainly with overdose and transmission of infectious diseases but also 
with a number of additional risks that were extensively summarised elsewhere is the most 
harmful route of administration. Reports of complications associated with intranasal 
administration are rare, while secondary asthma has been associated with heroin smoking, 
and cases of spongiform encephalopathy were ascribed to use of heroin by inhaling/ ‘chasing 
the dragon’ (Strang et al., 1998). 
4.1.2. Behavioural factors of harms related to heroin and other 
opioids 
Of all the substances under review, research on opioids focused on the most severe forms of 
use and the most severe harm — overdose, both fatal and non-fatal. Typically, the samples 
have been drawn from the population of injecting drug users. This creates a substantial bias 
towards daily and intravenous use, which are the main behavioural factors associated with 
negative consequences. Moreover, the severity of addiction and prevalence of psychiatric 
comorbidities increases with higher frequency of use, longer opioid using career, and with 
tendency towards injecting (Andersen et al., 1999; Darke et al., 2009). 
In some studies, samples of ‘controlled’ (i.e. non-problematic, controlling their use) heroin 
users have been identified, pointing to weekly use as a possible upper limit of controllable 
frequency of use (Shewan and Dalgarno, 2005; Shewan et al., 1998; Warburton et al., 2005). 
Measures of severity of dependence would perhaps be a better indicator of harmfulness in 
the case of opioids. Higher Severity of Dependence Scale (SDS) scores were associated with 
psychological morbidity, higher risk of overdose and suicide attempts (Darke and Ross, 1996; 
Gossop et al., 1996; McGregor et al., 1998; Kalyoncu et al., 2007; Powis et al., 2000). 
Similarly, duration of use appears to be connected to a number of negative consequences, 
including overdose; however, no indicator of severity can be extracted from the data as some 
users may control their use over many years (Zinberg, 1984). 
As mentioned above, in terms of negative consequences, the focus of the research has been 
mainly on overdose. Association was described with a longer drug-using career, polydrug 
use, and injecting. The relationship with frequency of use is not clear, as less frequent users 
may be at higher risk of overdose, possibly due to changing levels of tolerance (Brugal et al., 
2002). 
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Table 4.1: Overview of studies of opioid users 










Cut-offs / sample 
characteristics* 
Results Notes 
1. Darke et 
al. 
1996 Heroin injectors 
 


















10.9 yrs (sample 
average, SD=7.0) 
 







careers, greater heroin 
dependence and higher 
levels of alcohol 
consumption are 
independent predictors of 
heroin overdose.  
 
2. Gossop et 
al. 
1996 Heroin users out 
of treatment 
 














SDS: 9.1 average 
for the overdosed 
Overdose associated with 
injecting of heroin and 
severity of dependence; 
frequency of use was not a 





3. Ryan and 
White 
1996 Opioid users 
entering MMT 
 






Not specified Health status Frequency of use Not specified (n.s.) Association between 
perceived pain and 
amounts of drug 
consumed before 
treatment entry was the 
only significant. No other 
health indicators were 
correlated with use, 
making the relationship 
between health status and 
frequency of use unclear.  
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Cut-offs / sample 
characteristics* 
Results Notes 
4. Darke and 
Ross 
1997 Heroin injectors 
 



















Polydrug use n.s. Significant positive 
correlation was observed 
between number of 
lifetime drug dependence 
diagnoses and the number 
of lifetime anxiety and 
affective disorders, and 
the number of current drug 
dependence diagnoses 

























Intravenous, as compared 
to intranasal, opiate users 
have both a more severe 
pattern and a more 
extensive history of use, 





1998 Current heroin 
users 
 






Used heroin in the 
past 6 months 







SDS 6.4 (SD=4.1, 
sample average) 
 
9.6 yrs (SD=7.0, 
sample average) 
Frequency of alcohol use, 
length of heroin-using 
career, SDS scores and 
the total number of 
different drug types ever 
used were significantly 
related to having 
overdosed. 
 
Each additional point on 
the SDS (indicating higher 
levels of heroin 
dependence) increased 
the odds of ever having 
overdosed by 12 %. 
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Cut-offs / sample 
characteristics* 
Results Notes 
7. Shewan et 
al. 
1998 Opiate users out 
of treatment 
 





Used opiates at 
least 20 times in 








Frequency of use Heavy use (100+ 
times over past 2 
years) 
Severity of dependence 
increased for heavy users 
while remaining the same 
level for light and 
moderate users. 
 
In general, almost all 
participants self-reported 








1999 Opioid users 
among prisoners 
 
















Injecting dependent users 
were more severely 
affected than smoking 
dependent users with 
regard to somatic 
complications, early social 
strain, psychiatric 
comorbidity, personality 
dimensions, and cognitive 
performance. Non-
dependent injectors were 
more vulnerable than 
smokers subjects, both 
premorbid and during the 
dependence.  
 
9. Strang et 
al. 
1999 Heroin users 
 















to ‘chasing’ and 
never injected) 
Injectors were using higher 
daily doses and were 
significantly more likely to 
be using on a daily basis 
compared to ‘chasers’. 
Higher proportion of 
injectors was dependent. 
Chasers were generally 
less deeply involved in a 
heroin-using culture and 
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Cut-offs / sample 
characteristics* 
Results Notes 
10. Powis et 
al. 
2000 Mothers using 
opioids 
 






opiate use (use of 
illicit or non-
prescribed opiate 
drugs for at least 
1 year and on at 
least 4 days in the 
week prior to 
interview) 










Severity of dependence 
upon heroin was 





11. Brugal et 
al. 
2002 Heroin users in 
treatment 
 
N = 2556, age: 








Mental health Frequency of 
injecting 
 
















Cumulative risk of non-
fatal overdose increased 
as the frequency of heroin 
use decreased. Among 
daily heroin users this risk 
increased as the 
frequency of heroin 
injection rose. Sniffers had 
a higher risk than smokers 
among non-daily users, 
but not among daily users. 
 
12. Darke et 
al.* 

















to other routes) 
Non-injectors had lower 
levels of recent crime, 
shorter heroin using 
careers, fewer symptoms 
of dependence, had been 
enrolled in fewer previous 
treatment episodes and 
had less extensive 
polydrug use. They were 
less likely to report heroin 
overdoses. There were no 
differences between 
general physical and 
psychological health.  
 
page 16 of 53 










Cut-offs / sample 
characteristics* 
Results Notes 
13. Neale and 
Robertson* 




















SDS: 11.3 (SD=3.2, 
sample average) 
Injecting, higher SDS 
scores and use of other 
drugs besides heroin were 
significantly associated 
with recent (90 days prior 














Illicit use of 
opiates at least 10 
times in each of 















(Compared to light 
use of 25 days or 
less in the past 2 
years, and 
moderate use of 
25–50 times)  
 
While there was evidence 
of intensive risky patterns 
of drug use among the 
sample, there was equal 
evidence for planned, 
controlled patterns of use. 
Heroin was not a 
significant predictor of 
health problems. 
 
Frequency of heroin use 
was strongly associated 
with SDS scores, with 
moderate–heavy group at 
higher risk than less 














Used heroin at 
least once during 




n.a. n.a. Non-dependent users 
tended to follow rules that 
enabled them to restrict 
the frequency with which 
they used, and tended not 




dependent users (at least 
once per 6 months), 
frequent non-dependent 
users (once a month), and 
controlled dependent 
users (daily).  
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Cut-offs / sample 
characteristics* 
Results Notes 
16. Chamla et 
al. 











Not specified Risky patterns of 
use 
Duration of heroin 
injection 
6 months (to 
transition to 
injection) 
Short history of heroin 
injection was associated 
with sharing injection 
material. No differences in 
frequency of use were 
identified.  
 
Transition to injecting was 
associated with duration of 



















Index (ASI) score 
28+ (average for 
suicide attempters) 
Those who attempted 
suicide had a significantly 
higher ASI scores than 
















in the 30 days 
prior to the 
baseline interview 
 
Either had never 
injected drugs or, 
for former 
injectors, had not 
done so in the 
past 6 months 
Suicide Frequency of use  
 
 





Daily use/past 30 
days 
 
2+ bags of heroin 




Higher daily dose of heroin 
and shorter heroin-using 
career are predictors of 
transition to injecting.  
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Cut-offs / sample 
characteristics* 
Results Notes 
19. Darke et 
al.* 










Not specified Risky patterns of 
use 
Duration of use 9.6 yrs (SD=7.4, 
sample average) 
Each additional year of 
heroin use at baseline was 
associated with increased 
likelihood of: exposure to 
treatment, having been 
imprisoned, daily injecting, 
lifetime and recent 
polydrug use, having 
overdosed, poorer 
physical health and 
reduced likelihood of 
heroin smoking. Longer 
duration was associated 
across 36 months, 
however, with daily 
injecting, poorer physical 
health, severe physical 
















Not specified Health, criminal 
behaviour, risky 
patterns of use  
Any use of the 
drug 
Past month use of 
heroin or other 
opioids 
Drug use affects health of 
opioid users — poor health 
was predicted by past 
month heroin use and past 
month use of other 
opioids.  
 
Note:  * Studies with longitudinal design, typically prospective cohort studies. 
 ** Sample characteristics indicative for association with described harms are marked italics.  
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4.2. Cocaine and crack cocaine 
Cocaine is the most prevalent stimulant drug in Europe. It covers the whole spectrum of 
patterns of use from recreational and occasional to heavy and chronic use. A common search 
has been performed for cocaine and crack cocaine in the present review. Studies on primary 
‘speedball’ users who combine heroin and cocaine were excluded at this phase, as polydrug 
use was not a primary concern of this study. 
4.2.1. Harms associated with cocaine and crack cocaine — 
qualitative information 
On the drug market, cocaine is available either in the form of hydrochloride salt (‘powder 
cocaine’) that can be taken orally, intranasally by snorting, or dissolved and injected, or in the 
form of free base suitable for smoking or injection (‘crack cocaine’), which is considered to be 
the more addictive form of the drug. Smoking is the primary route of crack cocaine 
administration (Egred and Davis, 2005). Cocaine use is associated with a number of negative 
consequences. Cocaine-related health complications include cardiac, vascular, 
gastrointestinal, pulmonary, genitourinary and obstetric, neuroskeletal, musculoskeletal and 
dermatological problems (Cregler, 1989). Literature evaluating medical harms has focused 
mainly on cardiovascular problems, the most prevalent complication of cocaine use. 
Cardiovascular symptoms are dose- and route-independent (VanDette and Cornish, 1989; 
Lange and Hillis, 2001; Nademanee, 1992; Pitts et al., 1997; Afonso et al., 2007). For 
example, myocardial infarction has been reported in both first-time and chronic cocaine users 
and has been associated with all routes of administration (Cregler, 1991). However, the 
causal relationship between cocaine use and cardiovascular disorders remains under-
researched, as many factors may actually predispose individuals to cocaine toxicity 
(Knuepfer, 2003). Cerebrovascular complications include ischaemic disease, 
intraparenchymal and subarachnoid haemorrhage, atrophy and seizures (Brown et al., 1992; 
Treadwell and Robinson, 2007). 
In addition to the risk of blood-borne virus transmission associated with risky injecting 
practices and with needle sharing (Grund et al., 2010), several route- and form-dependent 
complications of cocaine use have been described. Pulmonary problems, including ‘crack 
lung’, are typical adverse effects associated with smoking free base cocaine, while septal 
necrosis and perforation or anosmia are complications associated with heavy intranasal use 
of cocaine (Glauser and Queen, 2007; Haim et al., 1995; Bates, 1988). Both cocaine and 
crack cocaine users are prone to developing severe dependence due to the reinforcing 
character of the experience (Arif, 1987).  
Changing patterns of cocaine use have been described. Siegel (1996) described a typology of 
patterns of cocaine use, widely applicable in the USA during 1970s. ‘Experimental use’ 
covered any short-term, non-patterned trial of cocaine with varying intensity and with a 
maximum frequency of 10 times’ lifetime use. ‘Social-recreational use’ generally occurred in 
social settings, typically on a weekly or bi-weekly basis, and use of the substance did not tend 
to escalate to more individually oriented patterns of use. ‘Circumstantial-situational use’, 
defined as task-specific, tended to occur four to five times per week and was achievement-
oriented and meant to enhance performance. ‘Intensified use’ was defined as long-term daily 
use motivated by a need to relieve oneself from stress, whereas ‘compulsive use’ was defined 
as high-frequency and high-intensity levels of relatively long duration resulting in some degree 
of dependence. The author notes that these patterns of use changed rapidly during the next 
decades when doses increased considerably and new patterns emerged, including 
dangerous binges (Siegel, 1996). 
Crude estimates describe four to eight times higher mortality among cocaine users than in the 
general population; however, existing studies have focused on socially disadvantaged, daily 
or dependent cocaine injectors or crack smokers, who may have a higher mortality risk than 
regular or dependent cocaine users who snort the drug (Degenhardt et al., 2011b). Cocaine 
overdoses are often associated with concurrent opioid use; solely cocaine use can 
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nevertheless lead to death due to a variety of sudden causes, including stroke, cocaine-
induced seizures and cardiac complications (Lange and Hillis, 2001; Glauser and Queen, 
2007; Cregler, 1989, 1991). 
4.2.2. Behavioural factors of cocaine and crack cocaine related 
harms 
Similar to studies on opioid users presented in the previous section and to studies on 
amphetamines users, there is substantial variability in measures of severity of cocaine use 
and associated outcomes. The sample of studies reported here is also heterogeneous in 
terms of the methods used and populations considered. Another level of complexity is 
connected with the duality of cocaine and crack cocaine.  
In cocaine studies, unlike amphetamines studies (see below), researchers often take into 
account the type of drug and route of administration as possible factors of adverse effects. 
The relationship is not, however, a clear one. Even though it may seem that crack cocaine is 
a more harmful drug, the findings often suggest a confounding role of patterns of use in terms 
of intensity and frequency (Haasen et al., 2005). Cocaine injectors and crack cocaine 
smokers are often involved in more dangerous lifestyles and use the drug on a daily basis or 
more often, which subsequently puts them at risk of negative consequences (Gossop et al., 
1994; Lexau et al., 1998). The nature of health consequences may, however, differ according 
to the route of administration. 
In terms of frequency of use, daily or every second day use seem to have the strongest 
association with unhealthy lifestyles, impairment in physical and mental health, involvement in 
riskier sexual behaviours and the highest dependence levels. High-frequency use is 
associated, especially among women, with involvement in human immunodeficiency virus 
(HIV)-risk behaviour (DeBeck et al., 2011; Edlin et al., 1994; Ferri and Gossop, 1999; 
Hoffman et al., 2000). Weekly use, especially when maintained for a longer period of time, 
may be considered to be harmful use as it is associated with a number of adverse outcomes 
and a low probability of positive change (Chen et al., 1996; Newcomb et al., 1987; Falck et 
al., 2000a, 2000b). Negative consequences are also prevalent among infrequent users and 
may be accounted for not only by the acute effects of cocaine, but also by polydrug use or 
routes of administration (Kaye and Darke, 2004a; Kuzenko et al., 2011). 
Duration of drug-using career has been positively associated with injecting, risk of overdose 
and higher levels of dependency; nevertheless, the direction of the relationship is difficult to 
determine due to methodological limitations (Kaye and Darke, 2004a, 2004b). 
Cocaine injecting (especially when frequent) and smoking put users at a higher risk of 
negative consequences and are often associated with higher levels of dependence (Gossop 
et al., 1994). Injecting is positively associated with HIV seropositivity even when the frequency 
of injecting is low (Tyndall et al., 2003). In addition, frequent users of intranasal/snorted 
powder cocaine are likely to transit to the riskier routes of administration.  
Polydrug users of cocaine were characterised by more severe patterns of use, including 
injecting (or were at higher risk of switching to injecting), and were more likely to attempt 
suicide (Shearer et al., 2007; Dunn and Laranjeira, 1999; Darke and Kaye, 2004). 
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Table 4.2: Overview of studies of cocaine and crack-cocaine users 
N. Authors* Year Population / 
sample 












1986 Young adults 
 





Not specified Risky patterns 
of use, health 
Frequency of 
use 
1+ times per week 
in the past 6 
months 
Cocaine abusers were 
less healthy, more 
troubled, heavier 
polydrug users, and 

















Any use of any form of 
cocaine in the past 12 
months 
Dependence Frequency of 
use 
12+ times in past 
12 months  
 




dependence were found 
in the frequency 
variables. There 
appeared to be no 
association between 
dependency and route of 
administration. This may 
be because the 
intravenous and smoking 
routes of administration 
are most often associated 
with the compulsive or 
frequent use of cocaine 
and a contribution was 
already accounted for by 






1991 Cocaine users 
in the general 
population 
 




Aged 18+ and residing 





Daily use Daily users reported 
cocaine consequences 
three to five times more 
frequently than all other 
identified cocaine users. 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 
4. Frischer et 
al. 
1993 Injecting drug 
users 
 





Injected drugs in the 










Polydrug use and 
polydrug injecting, and 
duration of injecting were 
all significantly higher 
among injecting cocaine 
users compared to 
injectors of other drugs. 
Cocaine injectors had 




5. Edlin et al. 1994 Regular crack 
smokers in the 
street sample 
of young adults 
 
N = 






Smoked crack at least 
3 days each week in 













Crack smoking was 
associated with high-risk 
sexual practices and led 
to high prevalence of 
sexually transmitted 














Used at least four 
times in the month 
prior to interview 
Dependence Route of 
administration 
Injecting/smoking  Route of drug 
administration was 
related to severity of 
dependence. Cocaine 
taken by injection was 
associated with the 
highest levels of 
dependence; intranasal 
use was associated with 
the lowest levels, and 
crack smoking was 
intermediate between the 
two. 
‘An SDS 
score of 5 is 
equivalent to 
reporting a 
low level of 
dependence 
on each of 
the five 
items.’ 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 






N = 532, age: 







None.  Physical health Frequency of 





months used at 




used cocaine or 
used it less than 10 
times 
 
Light use: approx. 
2–3 times a month 
 
Limited heavy use: 
at least once a 
week for a total of 
12 months or less 
at that frequency 
 
Chronic heavy use: 
at least once a 
week for 13 months 
or longer 
Chronic cocaine use 
increased physical health 
problems, controlling for 
prior health status, 
current cocaine use, use 
of other drugs and 
sociodemographic 
characteristics. Both 
frequency of use and 
number of years’ use 
since adolescence were 
substantially and 
significantly related to the 
5 indicators of physical 
health. 
 



















Injecting Past or current 
intravenous (i.v.) users 
had more extensive drug 
use histories than non-i.v. 
users. More current and 
past i.v. cocaine-using 
groups reported testing 
positive for hepatitis. 
Former i.v. cocaine users 
reported more 
emergency room visits. 
They also reported more 
treatment for substance 
abuse and were 
convicted of more crimes. 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 
9. Dunn and 
Laranjeira 










Used cocaine or crack 





use at peak 
usage 
 
















Factors associated with 
transitions were: younger 
age at cocaine initiation, 
more frequent use at 
peak usage, initial use of 
cocaine by snorting or 
injecting, and experience 
with a wider range of 
drug classes. 
 










Regular use of cocaine 
(at least twice a week 
for a minimum of 3 
months) and recent 























month on average 
(SD=10.0) 
Crack cocaine users had 
more social and health 
problems, higher 
dependence levels, and 
higher involvement in 
crime than intranasal 
users. These problems, 
compounded by the 
larger doses being used 
and their greater 
involvement in 
prostitution, place crack 
cocaine users at higher 
risk from HIV infection 
and other sexually 
transmitted diseases, and 





11. Back et al. 2000 Outpatient 
cocaine users 
 
N = 91, age: 
n.s. 
 
Location: USA  
DSM-III-R diagnostic 
criteria for cocaine 
dependence 
Mental health n.a. n.a. High incidence of PTSD 
among cocaine-
dependent individuals; 
association with severity 
and frequency measures 
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N. Authors* Year Population / 
sample 










12. Falck et al. 
(b)* 
2000 Crack cocaine 
users out of 
treatment 
 





Never injected drugs 
 
Recent user of crack 







Weekly + (78 % of 
the sample at the 
baseline) 
Frequency of crack use 
was negatively related to 
scores on the physical 
functioning, social 
functioning and mental 
health subscales. 
 
13. Falck et al. 
(a) 
2000 Crack cocaine 
users out of 
treatment 
 
N = 443, age: 
38.4/35.9 yrs 




Never injected drugs 
 
Recent user of crack 
cocaine (urine test) 











frequency of crack use 
and health status. Self-
assessed addiction to 
crack was strongly and 
negatively associated 




2000 Female crack 
cocaine users 
 






Used crack cocaine at 
least once during the 
previous 30 days  
 
Never injected drugs at 











Daily use (30 
days/last month) 
 
5+ times/using day 
 
Females who used crack 
with the greatest 
frequency and the 
greatest intensity were 
the most heavily involved 
in risky sexual 
behaviours. They differed 
quite sharply from their 
lower-intensity and/or 
lower-frequency crack-
using counterparts in 
terms of their HIV risk 
behaviour involvement 













11–29 of the 
previous 30 
days. 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 












Injected a drug at least 
six times in the past 6 
months or used 
cocaine at least once 
during this period via a 
route of administration 















SDS score 4+ 
Non-injecting drug users 
were more likely to report 
physical problems directly 
associated with cocaine 
use, they were generally 
in better physical and 
psychological health, 
were more socially 
functional, and had lower 
levels of criminality than 
injecting drug users. 
Dependence was high in 
both groups and was 
associated with poorer 
physical and 
psychological health, 
regardless of the 






16. Tyndall et 
al.* 
2003 Injecting drug 
users 
 






Injected drugs within 
the past month 








Injecting cocaine use was 
predictive of HIV infection 
in a dose-dependent 
fashion. Compared with 
infrequent cocaine users, 
participants who 
averaged more than 
three injections per day 
were seven times more 
likely to contract HIV. In 
addition, the time to HIV 
infection was accelerated 
among regular cocaine 
injectors independent of 
concurrent heroin use. 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 











Used cocaine within 
the preceding 12 
months 



















36 days in past 6 
months (average) 
 









Injecting cocaine users 
were significantly more 
likely than non-injecting 
cocaine users to have 
attempted suicide, on 
more than one occasion. 
Injecting, female gender, 
and more extensive 
polydrug use were 
independent predictors of 
a suicide attempt. 
 
Injecting was associated 
with higher levels of use 










score of 1 
equates to 1 
use episode a 
day; greater 




less than 1 to 
less than 
daily use. 
18. Kaye and 
Darke (a) 
2004 Cocaine users 
 






Used at least once in 





















96/3 days in the 





5.0/0.7 SDS score 
The prevalence and 
extent of symptoms was 
greater among injecting 
cocaine users; route of 
administration did not 
prove to be a significant 
independent predictor of 
harm. Factors 
engendered by injecting, 
such as more frequent 
use and higher levels of 
dependence, result in 
higher levels of harm, 
rather than the route of 
administration per se. 
Physical and 
psychological problems 
were also reported 
among infrequent users, 
suggesting that cocaine 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 
irrespective of frequency 
or method of use. 










Any use of cocaine in 



















12.6 yrs average for 
ever overdosed 
 
SDS 6.4 average 
for ever overdosed 
 
65.8 days/past 6 
months average for 
ever overdosed 
Cocaine injectors were 
more likely to have 
overdosed, both ever and 
in the past 12 months. 
Those who had 
overdosed were more 
likely to be female, had 
longer cocaine use 
careers, had used more 
cocaine in the past month 
and past 6 months, had 
higher levels of cocaine 
dependence and more 
extensive polydrug use.  
Cocaine use 
in the past 
month was 
measured 































not on a specific drug 
treatment 







Type of drug 
14.4 (±11.1) 
days/past 30 days 
(sample average) 
 






Mental health problems 
were influenced by age, 
gender, social situation, 
crack use, days of 
cocaine use in the past 
month, lifetime use of 
cocaine, severity of 
dependence, and 
physical health. In a 
regression analysis, 
intensity of use, physical 
health, severity of 
dependence and social 
situation were found to be 
predictors of mental 
health problems, while 
crack use by itself was 
not. 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 
21. Falck et 
al.* 
2007 Crack cocaine 
users 
 






Self-report the recent 











days (average for 
non-quitters) 
Crack cocaine users with 
low probability of 
abstinence had higher 
frequency of use in the 
past 30 days. 
 
22. Shearer et 
al. 
2007 Cocaine users 
 







Use of cocaine in the 























The majority of cocaine 
users classified as 
socially and economically 
integrated. A second 
group of socially and 
economically 
marginalised users 
injected cocaine often in 
conjunction with heroin, 
reported significantly 
higher levels of cocaine 
use, cocaine 
dependence, criminal 











N = 449 pairs, 






DSM-IV criteria for 
dependence 
 
Mental health Days of use in 
the heaviest 
period of use 
Not specified Psychiatric disorders are 
associated with an 
increased likelihood of 
cocaine dependence 
treatment or self-help 
group participation, but 
with only one of six 
indices of cocaine 
dependence severity. 
Severe psychiatric 
disorders such as bipolar 
disorder or ASPD may be 
associated with extended 
periods of heavy cocaine 
use. 
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N. Authors* Year Population / 
sample 






Cut-offs / sample 
characteristics** 
Results Notes 
24. DeBeck et 
al. 
2011 Injecting drug 
users 
 
















Daily crack cocaine 
use 
Intensity of drug scene 
exposure was associated 
with indicators of 
vulnerability to harm in a 
dose-dependent fashion. 
Factors associated were: 
daily crack use, daily 
cocaine injection, and 
daily heroin injection. 
 














None.  Mental health Number of uses 
in lifetime 
5+ uses/lifetime The risk for psychotic 
symptoms was higher in 
those with lifetime use of 
cocaine 5 or more times 
in comparison with those 
with use of a substance 
0–4 times.  
 
Note:  * Studies with longitudinal design, typically prospective cohort studies. 
 ** Sample characteristics indicative for association with described harms are marked italics.  
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4.3. Amphetamines 
Within the timeframe of the present review (from 2000 onwards), a growing prevalence of use 
of amphetamine-type drugs by heavy or problematic users emerged later than problem opioid 
or cocaine use in the EU and in most ‘western’ countries (for a history of amphetamines use 
in Europe see EMCDDA, 2010). The literature covered in this section is therefore more recent 
than in previous chapters. Both amphetamine and methamphetamine in their various forms 
(powder, crystal, base) are considered. Other derivatives of amphetamine, such as MDMA 
and related substances typically used on an occasional basis or ‘recreationally’, are not 
included in the analysis. 
4.3.1. Harms associated with amphetamines — qualitative 
information 
The available literature describes a number of consequences and adverse effects of regular, 
heavy or chronic use of amphetamines. While some authors distinguish between 
amphetamine and methamphetamine, others use the umbrella term ‘amphetamines’. Different 
forms of amphetamines are suitable for different routes of administration. For example, 
amphetamine hydrochloride salt is soluble in water and can be injected or digested; it can be 
heated and inhaled; in the form of powder it can be snorted, swallowed or absorbed through 
rectal mucosa; methamphetamine base or ‘crystal meth’ is, outside Europe, usually smoked 
(Greene et al., 2008). Injecting methamphetamine is a traditional route of administration in 
some countries, namely in the Czech Republic and Slovakia (Zábranský, 2007; Griffiths et al., 
2008). Routes of administration and their contribution to risks associated with the use of 
amphetamines are widely recognised in the literature (see the next section), with 
administration techniques that deliver a high dose of the drug (injecting and smoking) and 
routes that bear a high risk of transmission of blood borne viruses (injecting) being related to 
the highest risks (Kaye and McKetin, 2005; Colfax et al., 2010; Slavin, 2004; Urbina and 
Jones, 2004; Sheridan et al., 2006; Darke et al., 2008; Degenhardt et al., 2010). However, 
seropositivity associated with major drug-related infectious diseases is high also among non-
injection stimulant users, possibly due to higher involvement in risky sexual behaviour (Grund 
et al., 2010; Klee, 1992). 
Various adverse health effects of amphetamines have been described. Evidence exists about 
the toxicity (Darke et al., 2008; Cho and Melega, 2001; Gouzoulis-Mayfrank and Daumann, 
2009; Albertson et al., 1999), neurotoxicity (Gouzoulis-Mayfrank and Daumann, 2009, 
Nordahl et al., 2003; Back et al., 2000; Scott et al., 2007; Davidson et al., 2001; Meredith et 
al., 2005), and cardiotoxicity of amphetamines (Kaye and McKetin, 2005; Kaye et al., 2007). 
Although the dose-dependent nature of harms related to the use of amphetamines is often 
thought to be obvious, in some cases (such as cardiovascular complications) the relationship 
is not clear due to the effect of tolerance (Kaye and McKetin, 2005). 
Dependence and abuse are common outcomes of chronic use of amphetamines (Cho and 
Melega, 2001; Sheridan et al., 2006; Darke et al., 2008). Impairments in psychosocial 
functioning and mental health have also been described, with psychotic symptoms being the 
most common psychiatric problem, but an association with a number of personality disorders, 
major depression, violent behaviour, and suicidal tendencies has also been examined 
(Romanelli and Smith, 2006; Urbina and Jones, 2004; Grund et al., 2010; Maxwell, 2005; 
Marshall and Werb, 2010; Darke et al., 2008; Meredith et al., 2005; Lichlyter, 2009; Sheridan 
et al., 2006; Barr et al., 2006).  
Despite the association of amphetamines with excess morbidity, mortality among 
amphetamine users is relatively low compared to other ‘problem drugs’ and it is associated 
with longer drug careers and with injecting (Singleton et al., 2009). Deaths related to use of 
amphetamines are often caused by infectious disease/s or damage to the cardiovascular 
system (Sheridan et al., 2006; Darke et al., 2010). Amphetamine-induced overdoses 
constitute only a small proportion of fatal overdoses in the EU and worldwide, where they are 
mainly associated with opioid use (Grund et al., 2010). Direct amphetamine-related mortality 
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typically occurs due to heart attacks, seizures, cardiac arrhythmias or respiratory failures 
(Darke et al., 2008). Non-fatal overdoses related to amphetamine use, on the other hand, are 
a common phenomenon (Colfax et al., 2010; Darke et al., 2008; Albertson et al., 1999). 
4.3.2. Behavioural factors of amphetamines-related harms 
As was the case for opioids and cocaine, research on amphetamines is very heterogeneous 
in terms of the populations studied, methods used and the focus on various outcomes 
associated with the use of amphetamines.  
In terms of frequency of use, daily use of amphetamine or methamphetamine is considered to 
be the most harmful pattern, often leading to adverse outcomes in the health and 
psychosocial functioning of users (Hando et al., 1997; McKetin et al., 2008b). However, the 
typical threshold signalling a high risk of developing dependence starts at weekly use of the 
drug, referring either to the six or 12 months preceding the interview (Baker et al., 2001; 
Wilkins et al., 2004). It should also be noted that in some reported cases the users 
experienced problems even after relatively low exposure to (meth)amphetamine (Degenhardt 
and Topp, 2003). 
The duration of drug-using career has been a significant predictor of negative outcomes in 
many cases, but no threshold can be defined that would distinguish a phase of recreational 
use from becoming a chronic user. 
Amphetamine dependence, operationalised either as a clinical diagnosis following DSM-IV 
criteria, or as an SDS score equal to 4 or 5 and higher, was associated with a higher risk of 
developing health problems, financial problems and subsequent involvement in criminal 
activities, and with a tendency to suicide (McKetin et al., 2008a). 
In a majority of studies that regarded route of administration as a contributing factor, injecting 
was positively associated with negative consequences, including those not involving 
transmission of infectious diseases. The second most harmful pattern of administration was 
smoking crystal methamphetamine. In the association between harm and route of 
administration of amphetamines, risky patterns of use and chaotic lifestyles appear to 
contribute to or mediate the effect (Matsumoto et al., 2002; Zweben et al., 2004; McKetin et 
al., 2005). Bingeing, or the consecutive use of the drug for 48 hours and more, is especially 
typical for injecting and smoking users and is associated with impaired health (Hando et al., 
1997). 
When comparing the two main types of amphetamines used, methamphetamine seems to be 
equally or more harmful than amphetamine, even when recreational users of 
methamphetamine were compared with heavy users of amphetamine. However, only few 
studies examined the impact of specific type of amphetamine on harms inflicted (Degenhardt 
and Topp, 2003; McKetin et al., 2006). 
A final remark concerns polydrug use: the risk of adverse health effects and of problematic 
psychosocial functioning increased with each additional substance (or category of 
substances) used by amphetamine users. This relationship was apparent in all studies that 
covered the use of multiple substances (McKetin et al., 2008a; Hall and Hando, 1994, 1996). 
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Table 4.3: Overview of studies on amphetamines users 










Cut-offs / sample 
characteristics** 
Results Notes 














monthly for the 














7.3 yrs (SD = 5.8,) 
 
 




Injecting associated with 
higher level of dependence. 
 
Higher levels of polydrug 
use, greater amphetamine 
dependence, poorer social 
functioning and more 
frequent amphetamine use 
were significantly related to 



















for the past 6 
months 
 
Mental health Frequency of 




















and violent behaviour 
increased in prevalence 
after the onset of 
amphetamine use. Route 




predictors of overall 
psychological morbidity, 
while route of 
administration was related 
to the experience of 
hallucinations, violent 
behaviour and paranoia. 
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Cut-offs / sample 
characteristics** 
Results Notes 













monthly use of 
amphetamines 
during the past 
















Duration 6.7 yrs 
(SD = 5.5) 
 
36 days/past 6 
months (average), 
the equivalent of 
once or twice a 
week  
 
Daily use/past 6 
months (3 %)  
 
Bingeing 48+ hours 
(65 %) 
 
64 % ever injected, 
54 % mainly 
injected 45 % 
snorted/ swallowed 
Substantial harm 
associated with the use of 
this drug was found, most 
notably psychological 
problems, physical health 
problems, dependence and 












7.5) with a 
mean of 
10.5.  
























10.6 years (SD = 




71.9 % of the sample were 
classified as being 
dependent on 
amphetamine; 51.6 % 
reported that they had 
tested positive to hepatitis 
C virus, 18.8 % to hepatitis 
B virus and 4.7 % reported 
being HIV seropositive. 
76.6 % obtained a score of 
4 or more on the GHQ-28, 
indicating probable 
‘caseness’. Nearly one-fifth 
(18.8 %) of the sample 
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Mental health Route of 
administration 
Injecting/smoking Smokers experienced their 
first psychotic episode 
sooner after first 
methamphetamine use, but 
showed fewer auditory 
hallucinations. Group 
initially smoking and later 
injecting was intermediate 
between groups of 
exclusive smokers and 
injectors in life background, 
clinical features and 
psychotic symptoms, while 
they had lost control of their 
drug use most frequently. 
 
6. Degenhard




















Despite relatively recent 
and infrequent use of 
crystal methamphetamine, 
users experienced 
significant side effects 
related to their use. 
Compared with a sample of 
longer-term, heavier, and 
predominantly injecting 
amphetamine users, crystal 
meth users appeared likely 
to experience significant 
harms at a much more 
recent and lower level of 
use.  
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7. Wilkins et 
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amine at least 
monthly over 
the past 6 
months 






Smoking (54 %), 
snorting (22 %), 
injecting (20 %) 
 
Duration: 6 yrs 
average 
 
Twice a month 
(24 %); once a 
week (18 %); 
weekly+ (60 %) 
About one-fifth of the 
frequent users were having 
difficulties controlling their 
methamphetamine use. 
The most serious problems 
were psychological rather 
than physical; various 
physical harms were also 
listed. Levels of 
psychological problems 
reported after use were 
very high.  
 













criteria for MA 
dependence 









High levels of psychiatric 
symptoms, particularly 
depression and attempted 
suicide, but also anxiety 
and psychotic symptoms 
were identified in the 
sample. They also reported 
high levels of problems 
controlling anger and 
violent behaviour, with a 
correspondingly high 
frequency of assault and 
weapons charges.  
Higher score were 
observed for injectors (vs. 
non-injectors) and were 
positively correlated with 
frequency of use.  
 














mine at least 






























who committed crime were 
likely to be using 
methamphetamine 
frequently, taking the more 
pure forms of base or ice, 
and using a range of other 
drugs. Involvement in drug 
dealing was more strongly 
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methamphetamine was the 
key predictor of poor 
physical and mental health 
among users of the drug. 
Methamphetamine injectors 
had similar levels of 
injecting risk behaviour, 
including needle and 
syringe sharing, to that 
reported in other 
populations of injecting 
drug users. Rates of 
psychosis among regular 
methamphetamine users 
were 11 times that seen 
among the general 
population. 
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Participants who had used 
crystalline 
methamphetamine in the 
past year were significantly 
more likely to be dependent 
on it than participants who 
only took other forms of the 
drug. Methamphetamine 
dependence was 
associated with injecting or 
smoking (compared to 
intranasal or oral use), 
using methamphetamine 
more than weekly, having 
used the drug for more than 
5 years, and having used 
‘base’ methamphetamine in 








amine users in 




amine for a 











Virtually all of the 
respondents experienced 
negative consequences of 
methamphetamine use 
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(including seizures and 
convulsions, weight lose, 
depression, hallucinations, 
and paranoia). A significant 
number of sample 
members experienced 
limited or no serious social, 
psychological, or physical 




t et al. 
2008 Regular injecting 
drug users 
 
N = approx. 913, 







injection in the 









use: less than 90 





use: every second 
day or more/past 6 
months 
Frequent crystal use among 
regular injecting drug users 
is associated with earlier 
initiation to injecting, 
greater injection risk 
behaviours and more 
extensive criminal activity. 
 















 Dependence Frequency of 
use 
 















users reported more 
frequent methamphetamine 
use and higher levels of 
dependence. Compared 
with those who had used 
only other forms of 
methamphetamine, recent 
crystal methamphetamine 
users were more likely to 
‘binge’, engage in crime 
and experience financial 
and legal problems related 
to drug use. The 
association between crystal 
methamphetamine use and 
dependence was 
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of methamphetamine use 
and injecting drug use. 
14 McKetin et 
al. (b) 
2008 Users of 
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Smoking was associated 
with less severe 
dependence than injecting, 
but more intense use 
patterns and similar levels 






score 8+ for 
severe 
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17 years (median) 
 
Participants who reported 
physical impairment were 
more likely to be dependent 
on methamphetamine, 
inject the drug and have 
used methamphetamine for 
longer and on more days in 
the past month. Participants 
who had used the drug for 
at least 10 years were 
significantly more likely to 
report physical impairment, 
with increasing impairment 
associated with more 




















amine in the 
last 12 months 






Monthly use (27 %) 
or less often 
(56 %), weekly+ 
(17 %)  
 
31 % smoked, 
35 % swallowed, 
33 % snorted, one 
participant injected 
Psychotic symptoms in the 
past year were predicted by 
meth use and heavier 
polydrug use in the past 
year, and a history of a 
psychotic disorder. After 
removing participants with a 
history of a psychotic 
disorder and adjusting for 
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increased the probability of 
two or more psychotic 
symptoms (indicative of 
psychosis risk) from 9 % to 
21 %. 














None Mental health Number of 
uses during 
lifetime 
5+ uses/lifetime The risk of psychotic 
symptoms was higher in 
those with lifetime use of 
amphetamine 5 or more 
times, in comparison with 
those with use of a 
substance 0–4 times. 
 
Note:  * Studies with longitudinal design, typically prospective cohort studies. 
 ** Sample characteristics indicative of association with described harms are marked italics.  
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5. Discussion 
This literature review provides background information to enable decisions to be made on 
what may be considered harmful use of opioids, cocaine and crack cocaine, and 
amphetamines.  
For the stimulants under review, cocaine and amphetamines, the findings seem consistent 
and indicative. While it appears that users of stimulant-type drugs may be positioned 
somewhere on the continuum between experimentation and heavy use, opioid users appear 
to fall either among controlling users or, at the other end, daily users. The evidence on 
possible cut-off points for opioid use is therefore much less straightforward, because many 
studies focused almost exclusively on the latter group. Indexes of severity of addiction then 
often served as a proxy of the harmfulness of use of the drug.  
Although polydrug use was not a primary focus of the review, it emerged in all contexts as an 
important factor associated with physical and mental health problems, with worse social and 
economic functioning and involvement in criminal activities. By polydrug use we include use 
in combination with alcohol, and not only various modes of mixing illicit drugs. This finding 
also highlights one of many limitations of the existing literature: the behavioural indicators 
based on frequency and intensity of use are only very crude predictors of harmfulness, and 
there are many other factors (e.g. personal susceptibility) moderating harmful consequences 
of drug use.  
This uncertainty indicates that there are a number of methodological caveats that should be 
mentioned. First, the research covered in this review is extremely heterogeneous in many 
aspects. Sampling strategies, target populations, measures of severity and outcomes vary 
across the studies, giving virtually no confidence in the comparability of the findings. 
Moreover, the majority of research was designed as cross-sectional, indicating solely an 
association, not causality. Samples are often (fully or partially) drawn from treatment setting 
or capture users at the treatment entry, which probably biases findings towards users with 
more problematic consequences. Possible sub-populations of users who have no contact with 
any kind of services are often not included, and very little is known about their using patterns 
and related risks and consequences. This is apparent especially in the case of opioids, where 
researchers focus predominantly on the heaviest forms of use and the most severe 
consequences. The authors of methodological papers (Best et al., 2003; Macleod et al., 2004; 
Room, 2006) expressed similar concerns. 
With regard to the process of data collection, we limited the scope of sources searched in 
terms of their focus on the three groups of substances. The review therefore does not take 
into account the most rapidly emerging global phenomenon of legal highs (see below). We 
also disregarded research on risks associated with different routes of administration 
regardless of the drug, as we believe that it has been summarised satisfactorily elsewhere 
(Rhodes and Hedrich, 2010; Strang et al., 1998). 
Although some studies identified by our search strategy also considered negative 
consequences other than mental and physical health, it should be stressed that health issues 
constitute the majority of outcomes under the present review. This may be due to the choice 
of key words that emphasised concepts as harm, complication, and consequence. These 
terms are probably commonly associated with effects on health rather than with 
consequences in social and economic functioning. We would therefore like to acknowledge 
that there might exist a non-negligible body of research that focuses primarily on issues such 
as involvement in crime, occupancy, social exclusion and other life circumstances that have 
been under-represented in the present review.  
A final comment must be made on synthetic stimulant-type drugs other than amphetamines, 
which were not covered by the present review as it focused solely on the substances included 
in the 2004–12 EMCDDA definition of PDU. It will be difficult to maintain the traditional 
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category of amphetamine-type stimulants or amphetamines (including stereoisomers of 
amphetamine and methamphetamine globally, and methcathinone in Eastern European 
countries) in future, as a number of ‘legal highs’ from the family of fenetylamines 
(amphetamines), cathinones or pyrovalerons with stimulating effects are used by injecting or 
other high-risk patterns, and/or used by problem drug users (injecting drug users). The 
category should probably be broadened to include ‘other synthetic stimulants’ (similarly to dg. 
F15 in ICD-10) or ‘synthetic stimulants’ including a broader range of substances (Van Hout 
and Bingham, 2012; Csák et al., 2013). 
Despite these limitations, some suggestions for the construction of case definitions for the 
PDU key indicator revision can be made on the basis of the present review. 
6. Conclusions  
6.1. Cocaine, crack cocaine and amphetamines 
Use of these drugs on a weekly basis or more often is associated with a number of adverse 
consequences; and injecting and smoking are associated with riskier patterns of use. Crack 
cocaine use is connected to more severe conditions than is powder cocaine. Similarly, use of 
amphetamines on a weekly basis or more often indicates a problematic pattern of use. The 
crystalline form of methamphetamine and injecting and smoking of amphetamines are linked 
to higher levels of dependence and numerous negative consequences.  
6.2. Opioids 
Among populations of opioid users there seems to be a clear distinction between small and 
sporadically studied groups of users controlling their opioid use, and populations of heavy, 
dependent, daily users. Most studies identified in this review referred to the latter group and, 
intrinsically, expected harm to be inflicted on all of its members. Typically, the severity of 
harm was then associated with severity of dependence as measured by a variety of tools.  
Facing a lack of supporting comprehensive research, clinical experience suggests that opioid 
use is no less harmful compared to the use of stimulants. Raising the potential cut-off point 
from daily use (as it might appear from the summaries above) to weekly (and more frequent) 
use, similar to that of stimulant drugs, thus seems a reasonable solution, supported by a 
limited number of small-sample studies. 
Injecting and smoking have been shown to be the most harmful routes of administration; 
however, the effect is likely to be moderated by frequency and duration of use. Users who 
inject are at risk of transmission of drug-related infectious diseases regardless of the 
frequency.  
6.3. Newly emerged substances 
It would seem practical to include newly emerged substance in the new PDU definition, given 
the similarity in patterns of use between traditional amphetamines and newly emerged 
synthetic substances (typically cathinones and phenethylamines), and taking into account 
their growing popularity among heavy users in some countries. An analogous situation 
already exists for opiates and opioids with regard to acknowledging existing populations of 
synthetic opioid users in some countries. 
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6.4. Recommendations/implications for further stages of the 
study 
Findings from the review suggests that weekly and more frequent use of opioids, cocaine and 
crack cocaine, and amphetamines places users at risk of adverse effects in physical and 
mental health and that such use is associated with worse living conditions and social 
functioning. Together with injecting, the most harmful route of drug administration, weekly use 
should be considered to be the theoretical threshold for the most harmful forms of drug use. 
More research is recommended on the patterns of use of opioid substitution treatment 
substances and associated harms, and on the harmful forms of use of newly emerged 
substances. We also recommend that both these groups of drugs should be considered when 
compiling country overviews of PDU estimates in future EMCDDA work. 
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